You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
The Authors' reply
  1. Grazia Grazzini1,
  2. Marco Zappa2,
  3. Stephen P Halloran3
  1. 1Screening Department, Cancer Prevention and Research Institute (ISPO), Florence, Italy
  2. 2Clinical and Descriptive Epidemiology Department, Cancer Prevention and Research Institute (ISPO), Florence, Italy
  3. 3Bowel Cancer Screening Southern Programme Hub, Postgraduate Medical School, University of Surrey, Guildford, Surrey, England
  1. Correspondence to Grazia Grazzini, Department of Screening, Cancer Prevention and Research Institute (ISPO), Viale A. Volta 171 50131 Firenze, Italy; g.grazzini{at}ispo.toscana.it

http://dx.doi.org/10.1136/gut.2011.237479

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors' reply The new data presented in Dr Zorzi's letter1 2 are a valuable contribution to the evolving evidence that colorectal cancer screening programmes that use an immunochemical faecal occult blood test (iFOBT) should expect a difference in clinical effectiveness between periods of …

    View Full Text

    Footnotes

    • Linked article 233023.

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles